Epigenetic control of myeloid cell differentiation, identity and function

Nature Reviews Immunology

Volumn 15, Issue 1, 2015, Pages 7-17

  Álvarez Errico, Damiana ^a   Vento Tormo, Roser ^a   Sieweke, Michael ^b   Ballestar, Esteban ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; TRANSCRIPTION FACTOR;

BLOOD; BONE MARROW; BONE MARROW CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINEAGE; DENDRITIC CELL; DNA METHYLATION; EPIGENETICS; GENE; GENE CONTROL; GENE EXPRESSION; GRANULOCYTE; HEMATOPOIESIS; HISTONE MODIFICATION; HOST RESISTANCE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TET2 GENE; TISSUES; ANIMAL; CYTOLOGY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; IMMUNITY; IMMUNOLOGY; METABOLISM; MYELOPOIESIS; PHENOTYPE;

ANIMALS; CELL DIFFERENTIATION; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY; INFLAMMATION; MYELOID CELLS; MYELOPOIESIS; PHENOTYPE;

EID: 84925546982     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3777     Document Type: Review

References (95)

1. De Kleer, I., Willems, F., Lambrecht, B. & Goriely, S. Ontogeny of myeloid cells. Front. Immunol. 5, 423 (2014).
2. Geissmann, F. et al. Development of monocytes, macrophages, and dendritic cells. Science 327, 656-661 (2010).
3. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693-705 (2007).
4. Fischle, W., Wang, Y. & Allis, C. D. Histone and chromatin cross-talk. Curr. Opin. Cell Biol. 15, 172-183 (2003).
5. Turner, B. M. Histone acetylation and an epigenetic code. Bioessays 22, 836-845 (2000).
6. Hendrich, B. & Bird, A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol. Cell. Biol. 18, 6538-6547 (1998).
7. Blattler, A. & Farnham, P. J. Cross-talk between site-specific transcription factors and DNA methylation states. J. Biol. Chem. 288, 34287-34294 (2013).
8. Bird, A., Taggart, M., Frommer, M., Miller, O. J. & Macleod, D. A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. Cell 40, 91-99 (1985).
9. Zemach, A., McDaniel, I. E., Silva, P. & Zilberman, D. Genome-wide evolutionary analysis of eukaryotic DNA methylation. Science 328, 916-919 (2010).
10. Irizarry, R. A. et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nature Genet. 41, 178-186 (2009).
11. Maunakea, A. K. et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466, 253-257 (2010).
12. Zilbauer, M. et al. Genome-wide methylation analyses of primary human leukocyte subsets identifies functionally important cell-type-specific hypomethylated regions. Blood 122, e52-e60 (2013).
13. Schlesinger, F., Smith, A. D., Gingeras, T. R., Hannon, G. J. & Hodges, E. De novo DNA demethylation and noncoding transcription define active intergenic regulatory elements. Genome Res. 23, 1601-1614 (2013).
14. Stadler, M. B. et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature 480, 490-495 (2011).
15. Goll, M. G. & Bestor, T. H. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 74, 481-514 (2005).
16. Piccolo, F. M. & Fisher, A. G. Getting rid of DNA methylation. Trends Cell Biol. 24, 136-143 (2014).
17. Wu, H. & Zhang, Y. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell 156, 45-68 (2014).
18. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935 (2009).
19. Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839-843 (2010).
20. Ito, S. et al. Te t proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333, 1300-1303 (2011).
21. He, Y. F. et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303-1307 (2011).
22. Dawlaty, M. M. et al. Loss of tet enzymes compromises proper differentiation of embryonic stem cells. Dev. Cell 29, 102-111 (2014).
23. Jeong, M. et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nature Genet. 46, 17-23 (2014).
24. Laiosa, C. V., Stadtfeld, M. & Graf, T. Determinants of lymphoid-myeloid lineage diversification. Annu. Rev. Immunol. 24, 705-738 (2006).
25. Wilting, R. H. et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 29, 2586-2597 (2010).
26. Broske, A. M. et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nature Genet. 41, 1207-1215 (2009).
27. Chen, L. et al. Transcriptional diversity during lineage commitment of human blood progenitors. Science 345, 1251033 (2014).
28. Kondo, M., Weissman, I. L. & Akashi, K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91, 661-672 (1997).
29. Wada, T. et al. Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors. J. Biol. Chem. 284, 30673-30683 (2009).
30. Trowbridge, J. J., Snow, J. W., Kim, J. & Orkin, S. H. DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. Cell Stem Cell 5, 442-449 (2009).
31. Challen, G. A. et al. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell 15, 350-364 (2014).
32. Sun, D. et al. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. Cell Stem Cell 14, 673-688 (2014).
33. Boehm, T. Evolution of vertebrate immunity. Curr. Biol. 22, R722-R732 (2012).
34. Hodges, E. et al. Directional DNA methylation changes and complex intermediate states accompany lineage specificity in the adult hematopoietic compartment. Mol. Cell 44, 17-28 (2011).
35. Mansson, R. et al. Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. Immunity 26, 407-419 (2007).
36. Ji, H. et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 467, 338-342 (2010).
37. Mossadegh-Keller, N. et al. M-CSF instructs myeloid lineage fate in single haematopoietic stem cells. Nature 497, 239-243 (2013).
38. Bocker, M. T. et al. Genome-wide promoter DNA methylation dynamics of human hematopoietic progenitor cells during differentiation and aging. Blood 117, e182-e189 (2011).
39. Accomando, W. P., Wiencke, J. K., Houseman, E. A., Nelson, H. H. & Kelsey, K. T. Quantitative reconstruction of leukocyte subsets using DNA methylation. Genome Biol. 15, R50 (2014).
40. Ronnerblad, M. et al. Analysis of the DNA methylome and transcriptome in granulopoiesis reveal timed changes and dynamic enhancer methylation. Blood 123, e79-e89 (2014).
41. Klug, M. et al. Active DNA demethylation in human postmitotic cells correlates with activating histone modifications, but not transcription levels. Genome Biol. 11, R63 (2010).
42. Klug, M., Schmidhofer, S., Gebhard, C., Andreesen, R. & Rehli, M. 5-Hydroxymethylcytosine is an essential intermediate of active DNA demethylation processes in primary human monocytes. Genome Biol. 14, R46 (2013).
43. Zhang, X. et al. DNA methylation dynamics during ex vivo differentiation and maturation of human dendritic cells. Epigenet. Chromatin 7, 21 (2014).
44. Scott, E. W., Simon, M. C., Anastasi, J. & Singh, H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265, 1573-1577 (1994).
45. Laslo, P. et al. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell 126, 755-766 (2006).
46. Feng, R. et al. PU.1 and C/EBPα/β convert fibroblasts into macrophage-like cells. Proc. Natl Acad. Sci. USA 105, 6057-6062 (2008).
47. Xie, H., Ye, M., Feng, R. & Graf, T. Stepwise reprogramming of B cells into macrophages. Cell 117, 663-676 (2004).
48. Bussmann, L. H. et al. A robust and highly efficient immune cell reprogramming system. Cell Stem Cell 5, 554-566 (2009).
49. Barneda-Zahonero, B. et al. HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages. PLoS Genet. 9, e1003503 (2013).
50. Kallin, E. M. et al. Tet2 facilitates the derepression of myeloid target genes during CEBPα-induced transdifferentiation of pre-B cells. Mol. Cell 48, 266-276 (2012).
51. Hashimoto, H. et al. Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res. 40, 4841-4849 (2012).
52. Hanna, J. et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 133, 250-264 (2008).
53. Di Stefano, B. et al. C/EBPα poises B cells for rapid reprogramming into induced pluripotent stem cells. Nature 506, 235-239 (2014).
54. Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289-2301 (2009).
55. Li, Z. et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118, 4509-4518 (2011).
56. Pronier, E. et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 118, 2551-2555 (2011).
57. Losman, J. A. et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621-1625 (2013).
58. Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11-24 (2011).
59. Sasaki, M. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488, 656-659 (2012).
60. Ko, M. et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc. Natl Acad. Sci. USA 108, 14566-14571 (2011).
61. de la Rica, L. et al. PU.1 target genes undergo Tet2-coupled demethylation and DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation. Genome Biol. 14, R99 (2014).
62. Hervouet, E., Vallette, F. M. & Cartron, P. F. Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation. Epigenetics 4, 487-499 (2009).
63. Lawrence, T. & Natoli, G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nature Rev. Immunol. 11, 750-761 (2011).
64. Mullican, S. E. et al. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev. 25, 2480-2488 (2011).
65. Chen, X. et al. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc. Natl Acad. Sci. USA 109, E2865-E2874 (2012).
66. Ishii, M. et al. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 114, 3244-3254 (2009).
67. Satoh, T. et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nature Immunol. 11, 936-944 (2010).
68. Heintzman, N. D. et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nature Genet. 39, 311-318 (2007).
69. Barish, G. D. et al. Bcl-6 and NF-κB cistromes mediate opposing regulation of the innate immune response. Genes Dev. 24, 2760-2765 (2010).
70. Adelman, K. et al. Immediate mediators of the inflammatory response are poised for gene activation through RNA polymerase II stalling. Proc. Natl Acad. Sci. USA 106, 18207-18212 (2009).
71. Ghisletti, S. et al. Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages. Immunity 32, 317-328 (2010).
72. Kaikkonen, M. U. et al. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol. Cell 51, 310-325 (2013).
73. Austenaa, L. et al. The histone methyltransferase Wbp7 controls macrophage function through GPI glycolipid anchor synthesis. Immunity 36, 572-585 (2012).
74. Lam, M. T. et al. Rev-Erbs repress macrophage gene expression by inhibiting enhancer-directed transcription. Nature 498, 511-515 (2013).
75. Medzhitov, R., Schneider, D. S. & Soares, M. P. Disease tolerance as a defense strategy. Science 335, 936-941 (2012).
76. Medzhitov, R. Origin and physiological roles of inflammation. Nature 454, 428-435 (2008).
77. Netea, M. G., Quintin, J. & van der Meer, J. W. Trained immunity: a memory for innate host defense. Cell Host Microbe 9, 355-361 (2011).
78. Quintin, J., Cheng, S. C., van der Meer, J. W. & Netea, M. G. Innate immune memory: towards a better understanding of host defense mechanisms. Curr. Opin. Immunol. 29C, 1-7 (2014).
79. Ostuni, R. et al. Latent enhancers activated by stimulation in differentiated cells. Cell 152, 157-171 (2013).
80. Quintin, J. et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 12, 223-232 (2012).
81. Saeed, S. et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 345, 1251086 (2014).
82. Cheng, S. C. et al. mTOR-and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345, 1250684 (2014).
83. Adib-Conquy, M. & Cavaillon, J. M. Compensatory anti-inflammatory response syndrome. Thromb. Haemost. 101, 36-47 (2009).
84. Foster, S. L., Hargreaves, D. C. & Medzhitov, R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447, 972-978 (2007).
85. Yang, X. et al. Epigenetic regulation of macrophage polarization by DNA methyltransferase 3b. Mol. Endocrinol. 28, 565-574 (2014).
86. Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787-795 (2012).
87. Shih, A. H., Abdel-Wahab, O., Patel, J. P. & Levine, R. L. The role of mutations in epigenetic regulators in myeloid malignancies. Nature Rev. Cancer 12, 599-612 (2012).
88. Quintas-Cardama, A., Santos, F. P. & Garcia-Manero, G. Therapy with azanucleosides for myelodysplastic syndromes. Nature Rev. Clin. Oncol. 7, 433-444 (2010).
89. Patel, J. P. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079-1089 (2012).
90. Xia, M. et al. Histone methyltransferase Ash1l suppresses interleukin-6 production and inflammatory autoimmune diseases by inducing the ubiquitin-editing enzyme A20. Immunity 39, 470-481 (2013).
91. Moore, K. J., Sheedy, F. J. & Fisher, E. A. Macrophages in atherosclerosis: a dynamic balance. Nature Rev. Immunol. 13, 709-721 (2013).
92. Hoeksema, M. A. et al. Targeting macrophage histone deacetylase 3 stabilizes atherosclerotic lesions. EMBO Mol. Med. 6, 1124-1132 (2014).
93. Cao, Q. et al. Histone deacetylase 9 represses cholesterol efflux and alternatively activated macrophages in atherosclerosis development. Arterioscler Thromb. Vasc. Biol. 34, 1871-1879 (2014).
94. Kruidenier, L. et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488, 404-408 (2012).
95. Rodríguez-Ubreva, J. et al. Pre-B cell to macrophage transdifferentiation without significant promoter DNA methylation changes. Nucleic Acids Res. 40, 1954-1968 (2012).